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Abstract
Radiopharmaceuticals contain radionuclides and pharmaceuticals. Research 
on radiopharmaceuticals has been increasing in recent years by increasing the 
importance of early diagnosis in diseases. It is generally accepted that investigation 
and development of new radiopharmaceuticals are time and resource consuming. 
Computational methods have provided exciting contributions to pharmaceutical 
research and development. The need for designing new radiopharmaceutical drugs 
enhances the importance of computational programs. At this point, the structure, 
chemical, physical and physicochemical properties of molecules should be pre-
dicted/evaluated by using computational methods. While these methods obtain 
useful estimates, they make it easier for researchers and clinicians to make the right 
choices. Also, by providing accurate and effective results, they contribute to reduce 
the cost of research and can be used to simulate complex biochemical situations 
before research helping us to avoid harmful effects of drugs. In this study, authors 
emphasis about radiopharmaceuticals and the computational tools related to the 
development of new radiopharmaceuticals.
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1. Radiopharmaceuticals
Radiopharmaceuticals are radioactive drugs that can be used either for diagnos-
tic or therapeutic purposes in nuclear medicine applications. In nuclear medicine, 
95% of radiopharmaceuticals are used in diagnosis and 5% of them in therapeutic 
usage [1, 2]. The pharmaceutical component directs radioactivity to the target 
site of the body (disease regions, organs). A radionuclide emits detectable signals 
from outside the organism for visualization or delivers therapeutic levels of radia-
tion dose to target sites. Radiopharmaceuticals are bound to accumulate in certain 
organs or tissues according to the physical, chemical and biological properties of 
the pharmaceutical part [1]. They are not chemically distinguishable from non-
radioactive analogues and participate in biochemical events in the organism [2]. 
Organ functions can be visualized by the radiation emitted by radionuclides in their 
structure. A pathological change that can lead/leading to abnormal function can 
be diagnosed at the molecular level without going to the morphological level. So, 
diseases can be treated quickly after imaging [1].
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With the widespread use of radiopharmaceuticals, the need for specialized phar-
macists as known radiopharmacists has increased. Radiopharmaceuticals should 
be prepared by radiopharmacists and administered by clinicians to the patient. 
The doses of radiopharmaceuticals are defined either millicurie or microcurie. The 
pharmaceutical form of the radiopharmaceuticals may be solutions, kit, capsules 
and aerosols. The amount of active substance in the radiopharmaceutical is at a low 
dose that does not have a pharmacological effect. The shelf life of a radiopharma-
ceutical depends on half-life of radionuclide. Quality control of radiopharmaceuti-
cals should be done before administration to patients.
A radiopharmaceutical optimal performance should have some characteristics. 
While the radiopharmaceuticals used for diagnosis emit gamma ray, the radiophar-
maceuticals used for treatment emit beta ray. Alpha and beta radiation, which have 
particle radiation, are not desirable for diagnosis due to high linear energy transfers 
(LET). Because this energy is completely absorbed in the body, some particles that 
can escape to the body and cannot reach the crystal in the imaging system [3].
The ideal radionuclide energy for imaging should be around 100–300 kilo elec-
tron volts (keV). The quality of image falls when it is above or below these energy 
values. In radiopharmaceuticals used for treatment, the energy should be higher 
than above 1 MeV.
Ideally, the effective half-life of a radiopharmaceutical should be greater than 
about 1.5 times the imaging time. This pro vides a good image between the maxi-
mum dose and the minimum dose that can be injected into the patient, so that the 
counting statistics and image quality are optimal. On the other hand, the effective 
half-life of radiopharmaceuticals used in treatment is indicated by hours and days.
The localization of radiopharmaceuticals should be high in the desired organs or 
tissues. Low dose for both, patient and personnel, is necessary of ideal radiophar-
maceutical. When the radioactivity ratio in the target/non-target area is low and the 
radiation dose increases in non-target areas, treatment or diagnosis efficiency of 
radiopharmaceuticals decreases. They must be non-toxic, sterile and pyrogen-free 
for patient compliance. Finally, radiopharmaceuticals must maintain their chemi-
cal stability during usage, should be cheap and easy to find, easy to prepare and 
appropriate quality controls [4].
2. Classification of radiopharmaceuticals
In general, four types of radiopharmaceuticals are used in medical practice. 
The first of these is ready to use radiopharmaceuticals. These products have a 
shelf life. Administration to the patient is performed after the radioactive decay 
is calculated. Iodine (I-123) capsules, I-131 hippurane, Gallium (Ga-67) citrate, 
Tallium (Tl-201) chloride, Xsenone (Xe-133) aerosol, Technetium (Tc-99 m) 
pertechnetate are the examples of this group. The second type of radiopharma-
ceuticals is radiopharmaceuticals obtained from semi-manufactured products. 
They are prepared by combining the kits with radionuclides that obtained from 
the generator. The third type of radiopharmaceuticals is prepared directly before 
use. Products of this group should be prepared and used immediately. Examples 
of this group are the particle accelerator products. The fourth type of radio-
pharmaceuticals is based on preparation of samples taken from the patient. The 
patient’s cell or plasma proteins are radiolabeled with radionuclide and given to 
the same patient. An example of this group is Tc-99 m radiolabelled WBC. The 
laboratories have different regulations and rules because of this, radiolabelling 
efficiency and cell viability should be checked for this group after radiolabeling 
process [5].
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3. Computational models for drug development
Every patient and disease are different. The personalized treatment approach 
can be better for each patient requires. The development of individual mechanistic 
models of the disease process offers the possibility of attaining truly personalized 
drug-based therapy and diagnosis. At this point, computational methods have 
provided exciting contributions to pharmaceutical research and development. The 
need for individual drug design enhances the importance of computational models. 
Infrared (IR), ultraviolet (UV) and nuclear magnetic resonance (NMR) spectra 
of the molecule to be predicted, are important and generated by computational 
approaches in order to characterize molecular structure. The compatibility of the 
target protein active site with the small molecule (or ligand) is examined, so more 
effective molecules could be designed by this way [6].
Computer-aided drug design has been established as a valuable tool for the 
design of new molecules, with many success stories since the 1980s. Pharmaceutical 
companies have invested substantially in bioinformatics approaches, and it has been 
predicted that such methodologies will have an important role in pharmacogenom-
ics and personalized medicine. The American Food and Drug Administration 
(FDA) accepted and expressed the importance of new biomarkers and radiophar-
maceuticals for personalizing treatments [7].
Mathematical models of drug design are used to guide drug research and 
development. Computational models provide the identification of the factors 
involved in the absorption, distribution, metabolism, elimination and access to the 
target region of the chemical components. It also exposes the dynamics involved in 
the interaction of the compounds with the target (receptor, enzyme, etc.,). These 
models are effective in analyzing the fate of drugs that have undergone biotransfor-
mation. It helps us to comment on the undesirable effects or toxic effects of drugs 
and to help us explain drug-drug interactions. The concept of virtual clinical trials 
and the integrated use of in silico, in vitro and in vivo models in preclinical develop-
ment could lead to significant gains in efficiency and order of magnitude increases 
in the cost effectiveness of drug development and approval [8].
The targeting agent is used as a starting point for the design of computer-
assisted drug active substance. Examples of targeting agents include receptors, 
enzymes, nucleic acids etc. Natural endogenous substances or drugs may be effec-
tors that occupy the effective surface of the targeting agent and affect the target 
positively or negatively. Computer aided drug molecule design and development 
studies are examined in two groups:
1. Based on effector (ligand) structure
• Quantitative structure-activity relationships analysis (QSAR)
• Pharmacophore analysis
2. Based on target structure
• Molecular docking
• Based drug design
It is aimed to interpret the structure of receptors by using the structure of molecules 
and acting on ligand structure. In method based on the target structure, it is aimed to 
design molecules that can act on the basis of the known receptor structure [6].  
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In summary, computational models can be used to simulate complex situations prior 
to testing in reality, allowing us to make these inevitable mistakes and helping us to 
successfully avoid their deleterious impacts of new proposed drugs.
4. In silico models
It is generally recognized that drug discovery and development are time and 
resources consuming. There is an ever-growing effort to apply computational 
power to the combined, chemical and biological space? in order to streamline 
drug design, development and optimization. Computer-aided or in silico design 
is being utilized to expedite and facilitate identification, optimize the absorption, 
distribution, metabolism, excretion and toxicity (ADMET) profiles and avoid 
safety issues. In silico modeling significantly minimizes the time and resource 
requirements of synthesis and biological testing. The aim is to enrich the group 
of molecules with the desired properties (active, drug-like, lead-like) and to 
eliminate those exhibiting unwanted properties (inactive, reactive, toxic, weak 
ADMET/pharmacokinetic profile).
The result is a compounds library and, by virtual screening using in silico 
methods, the number of molecules to be tested forward by experimental means, 
is considerably reduced. Structure-based library design is prejudiced by structural 
requirements for specific activity on a particular target and needs prior informa-
tion of the target structure (e.g., X-ray or nuclear magnetic resonance). The goal 
is to select existing compound from libraries or to design compounds with three-
dimensional complementarity (i.e., shape, size and physicochemical properties) 
to the target-binding site. New approaches can directly guide the design of virtual 
combinatorial libraries, which are first screened in silico for targeting complemen-
tarity, thus reducing the number of compounds will have to be synthesized and 
tested in vitro.
The “leading” compound has the desired pharmacolological or biological activ-
ity and represents the starting point to design other molecules with improuved 
properties/chemical parameters in terms of efficacy and pharmcokinetic profile, 
better candidates for future chemical synthesis and trials. When leading molecules 
have been identified, they have to be optimized in terms of potency, selectivity, 
pharmacokinetics and toxicology before they can become candidates for drug 
development. The early analysis in this respect is becoming common practice 
because the high overall attrition rate in drug discovery is affected the identifica-
tion of compounds. Traditionally, therapeutics have been small molecules that 
fall within the Lipinski’s rule of five [9]. From this point of view, hydrogen bonds, 
log P value, penetration into the targeting side can be mentioned. If the hydrogen 
bond donors are <5, the hydrogen receptors are <10, the relative molecular weight 
is <500 g/mol and the lipophilicity (log P) is <5, the compound will probably 
be orally bioavailable. The concepts of virtual library and virtual browsing have 
become an integral part of pioneering discoveries. In silico approaches signifi-
cantly contribute to early pharmaceutical research and are especially important 
in target and lead discovery. The need has been clearly recognized and is expected 
to improve efficiency of drug design for timely adaptation and application of in 
silico models in pharmaceutical research [10]. European policy for the evaluation 
of chemicals (REACH: Registration, Evaluation, and Authorization of Chemicals) 
has been a strong advocate of alternative in silico methods of predictive evaluation 
of chemical toxicity in order to minimize animal testing and conserve time and 
resources [11].
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5. Factorial Design for Drug Delivery
Design of Experiments (DoE) is defined as a planning strategy that will be 
carried out to obtain the information from the collected data effectively. It is a 
structural method used to determine the relationship between different factors 
(independent variable, input, process parameter, formulation component, etc.,) 
and their responses (dependent variable, response variable, output, product quality 
feature, etc.,). Also, this model is a mathematical model that correlates all the 
relevant factors and the results obtained against these factors. The results can be 
interpreted, predicted and the design space can be determined by optimization with 
this mathematical model. Systematic DoE approaches have advantages such as less 
experimental study, easier problem identification and prevention, any active agent 
adjuvant interaction and product performance to guarantee an effective formula-
tion, and process optimization for good results in the scale up process.
An ideal drug form design should be depended on the understanding of the 
physicochemical and mechanical transformations of the materials that will eventu-
ally turn into the desired product. However, due to the diversity and complexity of 
the drug components, it is usually not fully understood. Factorial design with a sys-
tematic approach the product and production process can be understood in depth. 
In this way, a development approach can be provided which takes into account the 
variability of the inputs and other risks that may arise against product quality.
It is very important to obtain the basic knowledge of the study in order to 
produce as much information as possible with the right modeling. The statistical 
analysis is the first stage of experimental work before optimizing the formulation. 
Simple models are used in statistical screening. For example, linear models with 
only the main factor effects, or linear models, including binary interactions. In 
this way, the factors that have the most effect on the outputs are determined with 
the least number of tests possible. Factors with little or no significant effect can be 
displayed. In addition, by decreasing the number of factors, optimization design 
with a smaller number of attempts can be used.
The choice of DoE should be based on the number and type of factors to be 
investigated. For example, if the goal is only to reduce the number of factors and 
find a few factors that have the highest effect on the outputs, and if there are too 
many factors to be investigated, then the statistical elimination by construct-
ing linear models can be selected. The results consist in lowering the number of 
attempts and evaluate only the main factor effects. The most preferred statistical 
screening methods in drug formulations are two-level partial full factorial design 
and Plackett-Burman design [12].
After statistical screening, response surface modeling (RSM) designs are started. 
The number of factors should be reduced by the statistical elimination design before 
the RSM design, so that the number of trials is not high and the statistical signifi-
cance is important/relevant or other synonym and strong prediction models can be 
established. RSM is an approach where statistical and mathematical techniques are 
used together for the development and optimization of pharmaceutical processes. 
Includes modeling techniques used to determine the relationship between depen-
dent variables and the independent variables that affect them.
RSM designs for drug formulations allow us to understand the relationship 
between factors and response variables, as well as factor interactions (synergistic 
effect of two or more factors), quadratic effects, and cubic terms. In this way, 
the optimum value ranges of the factors are provided. Process problems can 
be solved. Robust processes that are less sensitive to process variability can be 
developed.
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Each additional experiments and sample analysis performed to product devel-
opment in the pharmaceutical industry means that spending a lot of money, time 
and labor loss. The selection, implementation and interpretation of the appropriate 
factorial design that serves to reach the result accurately and rapidly is very impor-
tant. Selecting the appropriate experimental design ensures that development 
studies are completed with a small number of trials. In order to optimize the process 
and formulation, mathematical models are described that best relationship between 
these critical factors and quality characteristics [13].
6. Computational models for radiopharmaceuticals
Computer models in the pharmaceutical industry is used to discover new 
drugs, to optimize of chemical processes and to design clinical trials. Accurate 
computational estimation of the responses to the treatments and clinical 
profiles of administration is of great importance for patients [14–19]. Also, 
it is very useful to help clinicians decide on the most effective and least toxic 
treatment available options, and is significant for researchers to selecte for in 
vitro and in vivo studies [20–22]. In addition, the computational prediction of 
drug responses can substantially contribute to preclinical studies, as in silico 
drug screening model. These tools can help researchers in the selection of 
candidate compounds in their research, and can be used to improve efficiency 
in experimental planning and to reduce costs [23–25]. Especially, computational 
estimation of drug responses in cancer disease involves significant research 
challenges. It is a biological challenge since cancer is a very heterogeneous and 
multifactorial disease. Furthermore, increasing the need for data integration, 
new technical questions arise from multiple sources such as the adjustment and 
normalization of data from multiple sources [14]. In the Oak Ridge National 
Laboratory, Snyder [26] the first mathematical model of radiopharmaceuticals 
was realized. In this design, the fractions of energies and amount of gamma and 
X-rays emitted from radiopharmaceuticals in the targeting tissue were used by 
Monte Carlo method [26]. Computational model supports the development of 
radiolabeled complex synthesis and coordination chemistry of radiopharmaceu-
ticals by providing a better understanding of the physicochemical properties of 
molecular imaging agents. Combining experimental studies with computational 
study helps to define structure-activity relationships of radiopharmaceuticals 
and facilitates the rational design of new generation radiopharmaceuticals with 
improved properties. Francisco et al. [27] used different computational simula-
tors to investigate the therapeutic potential of various radionuclides. These 
simulators are:
• Fast Monte Carlo damage formation simulator.
• Fast Monte Carlo excision repair simulator.
• Virtual Cell Radiobiology Simulator [27].
Fast Monte Carlo damage formation simulator can be used to estimate the 
types of DNA damage and post-irradiation efficiency. This method allows mul-
tiple data analyzes with multiple irradiation estimates to be collected as soon as 
possible [28, 29].
Fast Monte Carlo excision repair simulator can be used to estimate the occur-
rence, repair of DNA and correct repair results by mutation [27].
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Virtual cell radiobiology simulator is a radiobiological model used to describe 
dose response relationship, damage production process and key repair mechanisms. 
These models often relate the dose rate to the cell’s response to irradiation. Some 
of the current models include a repair-false-repair model, a fatal potentially fatal 
model, and two lesion kinetics [28].
In one study, the Monte Carlo method was used to assess the amount of radio-
nuclide in animal models for preclinical testing of radiopharmaceuticals. In another 
study, this model predicted 3D images simulated with SPECT or PET for patient-
specific radionuclide treatments [27, 28].
Computational methods allow quick and easy data collection. However, some 
models are based on available information and are evaluated according to this 
information and this imposes some restrictions. The used algorithms report an 
optimal ionization scenario to ionize the DNA in place of ineffective radionuclide 
biodistribution process that is obtained by in vitro and in vivo studies under difficult 
conditions. Thus, although the validation of the used simulators has been per-
formed in selected irradiation scenarios and specific cellular populations, specify-
ing these methods may be useful as a first step approach to large data sets to assist in 
the planning of in vitro and in vivo studies [29–33].
Kurniawan et al. [34] studied on radiopharmaceutical ligands and concrete 
examples of molecular docking. T3, 4BCPP is an imidazolylporphyrin derivative 
and has been used as a radioimaging agent for melanoma cancers. They designed 
new imidazolylporphyrin derivatives with better selectivity and higher affinity than 
T3, 4BCPP by using AutoDock 4.2. After that they develop a new radiopharmaceu-
tical by using a radionuclide such as Technetium (Tc) for diagnostic and Rhenium 
(Re) for therapeutic purposes. They concluded that radiolabelled imidazolylpor-
phyrin derivatives could be two potential candidate ligands for a melanoma radio-
pharmaceutical kit.
Chen et al. [35] assessed the effects of structural modification on the interaction 
of 125I-labeled iodo Hoechst ligands and DNA. Also, they designed new analogs 
with specified distances between the Auger-electron-emitting 125I atom and the 
DNA central axis by using computer-assisted molecular modeling software. This 
software program has been obtained the reactivity of newly designed radiolabelled 
molecules with their targeted DNA molecules by molecular modeling prior to their 
chemical synthesis.
El-Motaleb et al. [36] developed an easy method for radio iodination of pro-
pranolol with high percent labeling yield for the purpose of lung perfusion imaging. 
They used molecular modeling and docking studies to ensure the binding of the 
newly obtained radio iodination of propranolol to beta-2 adrenergic receptor and 
confirmed that radio iodination did not affect the binding of propranolol to beta-2 
receptor by using molecular modeling.
7. Conclusion
Computational methodology provides some advantages such as creating time-
dependent organ dose rate curves, making easier for researchers and clinicians to 
take the right choices. Also, these approaches give accurate and effective results 
and reduce the cost of research being useful to simulate complex situations before 
research, to avoid harmful/side effects. Furthermore, the radiopharmaceutical 
dosimetry estimates demonstrate large variation due to the patient’s anatomical 
characteristics and computational model can be useful for obtaining personalized 
data. We believe that using these methods could enhance the personalization of 
dosimetry in nuclear medicine administration.
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